NEW YORK (GenomeWeb) – Rebiotix, a Rosewood, Minn.-based biotherapuetics developer, has adopted Genetic Analysis' microarray-based GA-map dysbiosis test for use in its R&D programs, the companies announced this week.
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.
Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.
In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.